These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11298060)

  • 41. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
    Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
    BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Goepel M
    Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities.
    Mahanta K; Medhi B; Kaur B; Narasimhan KL
    J Pediatr Urol; 2008 Apr; 4(2):118-23. PubMed ID: 18631906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up.
    Atan A; Konety BR; Erickson JR; Yokoyama T; Kim DY; Chancellor MB
    Tech Urol; 1999 Jun; 5(2):67-70. PubMed ID: 10458657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
    Reddy PP; Borgstein NG; Nijman RJ; Ellsworth PI
    J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
    Rovner ES; Wein AJ
    Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
    Tsujimura A; Takao T; Uchida K; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Hirai T; Kiuchi H; Miyagawa Y; Takahashi T; Kojimaan Y; Okuyama A
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):686-92. PubMed ID: 19999133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
    Leung HY; Yip SK; Cheon C; Liu YS; Lau J; Wong HK; Chung KH
    BJU Int; 2002 Sep; 90(4):375-80. PubMed ID: 12175392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.